Vital Infrastructure Property Trust

Second quarter same-property NOI on a proportionate group basis increased 2.3% year over year to $51 million; management also said overall same-property NOI would have been up 3.2% excluding the one-time outsourcing-related expense impact. FFO per unit excluding accelerated amortization of financing costs was 11 cents, and AFFO per unit was $0.11, up from 10 cents in Q1. AFFO payout ratio was 85%, down from 88% a year ago. Proportionate leverage improved to 46.8% from 52.7% in Q1 and 56% a year ago, while debt to adjusted EBITDA was 7.1x, or 7.7x on a comparable basis. Full-year outlook called for G&A excluding unit-based comp and severance of about $35 million by end-2026, and management reiterated a mid- to long-term leverage target around 50% or 8x debt to EBITDA. Management also said it had already completed or committed roughly $153 million of acquisitions after quarter end and had previously given soft guidance of about $250 million for the year.

The CEO framed the quarter as evidence that Vital’s multi-pronged transformation is working: simplify the footprint, strengthen the balance sheet, lower costs, and allocate capital more disciplinarily. He highlighted the European exit, internalization in New Zealand, and North American acquisitions as proof the company is becoming “simpler, stronger and more focused.” His tone was constructive and confident, especially around the pipeline, the company’s ability to recycle capital, and the long-term optionality in assets like Fairview and Healthscope.

The CFO focused on the mechanics of the quarter: same-property NOI up 2.3% to $51 million, FFO per unit at 11 cents, AFFO per unit at $0.11, and an 85% AFFO payout ratio. She noted G&A attributable to AFFO fell to $10 million from $12.2 million last year, with headcount down about 40% and a $35 million annualized G&A run-rate target by end-2026. On the balance sheet, she cited proportionate leverage of 46.8%, debt to adjusted EBITDA of 7.1x (7.7x comparable), over $250 million of available liquidity after quarter end, and the successful refinancing of AUD $715 million of Australian JV debt, extending maturity to December 2028.

Analysts focused on where the acquisition pipeline is concentrated, with management saying it is currently skewed about two-thirds toward the U.S., while Canadian development opportunities remain important. Questions also centered on Healthscope; management said the process appears to be moving toward resolution, that Vital supports the current consortium, and that it is too early to detail any rent concessions or final lease terms. Other notable discussion covered the use of post-disposition capital, with management saying proceeds from any Australian or New Zealand asset sales would likely be repatriated to North America, and that the company expects to be much simpler within 12 months and mostly North America-focused within about 24 months.